Eloxx Pharmaceuticals, Inc. (ELOX): Price and Financial Metrics

Eloxx Pharmaceuticals, Inc. (ELOX)

Today's Latest Price: $3.99 USD

0.06 (-1.48%)

Updated Jan 20 6:55pm

Add ELOX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ELOX Stock Price Chart Interactive Chart >

Price chart for ELOX

ELOX Price/Volume Stats

Current price $3.99 52-week high $6.77
Prev. close $4.05 52-week low $1.44
Day low $3.90 Volume 55,500
Day high $4.06 Avg. volume 71,650
50-day MA $3.44 Dividend yield N/A
200-day MA $3.05 Market Cap 160.21M

Eloxx Pharmaceuticals, Inc. (ELOX) Company Bio

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is based in Waltham, Massachusetts.

ELOX Latest News Stream

Event/Time News Detail
Loading, please wait...

ELOX Latest Social Stream

Loading social stream, please wait...

View Full ELOX Social Stream

Latest ELOX News From Around the Web

Below are the latest news stories about Eloxx Pharmaceuticals Inc that investors may wish to consider to help them evaluate ELOX as an investment opportunity.

CF Foundation Awards Up to $2M to Eloxx Pharmaceuticals for Additional Support of Phase 2 Clinical Studies of Potential Therapy for Nonsense Mutations

BETHESDA, Md.--(BUSINESS WIRE)--Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations. In 2019, the Foundation provided Eloxx with an award of up to $1.6 million to support the development of ELX-02 in the U.S. This additional funding will provide continued support for a Phase 2 proof-of-concept cli

Business Wire | January 13, 2021

Eloxx Pharmaceuticals (ELOX) in Focus: Stock Moves 6.9% Higher

Eloxx Pharmaceuticals (ELOX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Yahoo | December 16, 2020

Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Stocks News Feed

WALTHAM, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, is pleased to announce that Dr. Gregory Williams, Chief Executive Officer of Eloxx,… Read More »Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Stocks News Feed | November 18, 2020

Global Health Sciences Fund (Quark Venture LP and GF Securities) Announces Portfolio Company SQZ Biotechnologies’ IPO

VANCOUVER, British Columbia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Quark Venture LP (Quark) and GF Securities are pleased to announce the successful listing of portfolio company, SQZ Biotechnologies (NYSE: SQZ) (“SQZ”) on the New York Stock Exchange (NYSE) as of October 30, 2020. This announcement marks Global Health Sciences (GHS) Fund’s third portfolio company to successfully go public after Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) in April 2018 and Keros Therapeutics, Inc. (NASDAQ: KROS) in April 2020. As one of the early investors in SQZ in 2016, alongside Polaris Partners, NanoDimension and GV (formerly Google Ventures), Quark has continued to support the growth of the company to advance its proprietary CellSqueeze® technology and its application in developing impactful cell therap...

Yahoo | November 9, 2020

Eloxx Pharmaceuticals, Inc. (ELOX) Q3 2020 Earnings Call Transcript

Welcome and thank you for joining us this afternoon for a review of Eloxx Pharmaceuticals Third Quarter 2020 financial results and business update. Joining me this afternoon are Dr Greg Williams, our Chief Executive Officer, Neil Belloff, Chief Operating Officer and General Counsel, Dr Tom Haverty, our Chief Medical Officer, Dr Matthew Goddeeris, Vice President, Research and Steven McDonald, our Vice President of Finance and Accounting.

Yahoo | November 6, 2020

Read More 'ELOX' Stories Here

ELOX Price Returns

1-mo -1.24%
3-mo 34.80%
6-mo 35.71%
1-year -14.56%
3-year -53.60%
5-year -21.76%
YTD 0.25%
2020 -45.92%
2019 -38.72%
2018 50.13%
2017 185.31%
2016 -64.86%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.1676 seconds.